COVID-19 Disruption
Read more about the impact of COVID-19 on HIV, TB and malaria services and systems for health
download in English | Français
download in English | Français
Country-based Local Fund Agents, who monitor grant implementation and progress on behalf of the Global Fund, complete a monthly survey online to help identify potential risks and disruptions to programs. The tool is not meant to be a rigorous assessment of the country situation. The data is based on in-country stakeholder views but not on verified data. Key insights as of 1 November 2021:
Countries in lockdown: 33% of countries where the Global Fund invests are experiencing nationwide restrictions as of 1 November, remaining stable since 1 October. 15% of countries are still experiencing local restrictions that impact the programs run by the Global Fund, marking an improvement since 1 October.
Costed national plans: The share of countries with fully costed response plans in place for their COVID-19 response has slightly decreased. On 1 November 2021, 84% of countries had a costed response plan in place, compared to 85% on 1 September 2021, 83% on 15 November 2020, and 75% on 15 June 2020.
Disruption to health service delivery: The overall risk of disruption to all disease services continues to decline as of 1 November. Of the three diseases, malaria services continue to experience the highest level of disruption. 42% of countries are reporting no or low disruption to health service delivery for HIV, compared to 39% of countries for malaria and for TB. 3% of countries are experiencing very high disruption for malaria services, compared to 1% for TB services and 0% for HIV services.
Disruption to supply of key medicines: The risk trend for the supply of key HIV medicines has sharply increased as of 1 November. The risk trend for the supply of TB medicines continues to decline, while the risk trend for the supply of malaria medicines remains stable. For all three diseases, more than half of the countries where the Global Fund invests have a minimum 6 months’ supply capacity of key medicines. As of 1 November, 5% of countries were experiencing shortages for HIV medicines, while 3% of countries were experiencing shortages for TB and malaria medicines.
Lab services: As of 1 November, 48% of countries are reporting no or low HIV and/or TB lab services disruption, up from 43% on 1 October. 48% of countries are reporting moderate disruption, a slight improvement since 1 October. The percentage of countries experiencing high HIV and/or TB lab services disruption has slightly decreased from 4% on 1 October to 2% on 1 November. The share of countries reporting very high disruption has remained stable at 2% since 1 July.
